ARPA-H selects three firms to develop agentic AI for cardiac care
The federal ARPA-H program has chosen UpDoc, Tempus AI, and Atman Health to participate in a new initiative called ADVOCATE. The goal is to build FDA-authorized agentic AI tools to assist in managing heart disease. The program aims to integrate advanced AI into clinical workflows to improve patient outcomes.
The ADVOCATE initiative, managed by the federal ARPA-H program, brings together three distinct companies to develop autonomous AI systems for cardiac care. These tools are intended to eventually receive FDA authorization, marking a significant step in regulatory oversight of self-directed medical software.
By focusing on heart disease management, the program seeks to embed these agentic systems directly into existing clinical workflows. The overarching objective is to leverage advanced computational models to enhance decision-making and ultimately improve patient health outcomes.
The ADVOCATE program could reshape cardiac care by offering clinicians autonomous decision-support tools, potentially reducing diagnostic delays and standardizing treatment protocols. Patients with heart disease may benefit from more personalized and timely interventions. However, integrating such systems into daily practice may also require careful attention to clinician trust, liability, and patient data security, as these tools transition from research to FDA-authorized clinical use.